SLS SELLAS Life Sciences Group, Inc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Jun 2, 2026 Processed 4d 10h ago SEC 0001104659-26-069251
8-K context-dependent: Items 8.01
Latest settled — T+1d
SLS ▼ -1.68% at T+1d
NEUTRAL call ✗ call lost -1.68% · α vs SPY -0.99% · entry $8.33 → $8.19
Next anchor: T+5d in 3d
Currently $8.23 · -1.20% from $8.33 entry
Entry anchored
Jun 1, 03:59 PM ET
via Databento tick
T+1d
-1.68%
call -1.68% · α -0.99%
$8.19
settled 3d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 25d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds during April and May 2026, and reported 196,632,574 shares outstanding as of June 2, 2026. The company had $107.1 million in cash as of March 31, 2026. This is a routine capital structure update with no material operational or financial results.

Actionable Insight

The warrant exercise proceeds extend the cash runway modestly but do not change the fundamental outlook. Monitor the next quarterly report for updated cash burn rate and pipeline progress.

Key Facts

  • As of March 31, 2026, SELLAS had $107.1 million in cash and cash equivalents.
  • Received approximately $28.7 million in proceeds from common stock warrant exercises in April and May 2026.
  • As of June 2, 2026, the company had 196,632,574 shares of common stock outstanding.

Financial Impact

Cash balance increased by ~$28.7M from warrant exercises, adding to the $107.1M reported at Q1 end.

cashshares outstanding

Risk Factors

  • Dilution from warrant exercises is already reflected in the share count; further warrant overhang may remain.
  • No revenue or earnings data provided; cash runway and clinical trial milestones remain key catalysts.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-069251
Document: 0001104659-26-069251-index-headers.html0001104659-26-069251
Document: 0001104659-26-069251-index.html0001104659-26-069251
Document: 0001104659-26-069251.txt0001104659-26-069251
6 reports for SLS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SLS — sortable, filterable
Type Now
Jun 2, 2026
4d ago
8-K
NEUTRAL ★ 3/10
$8.33 $8.19▼ −1.68%▼ −0.99%$8.23 (−1.20%)
May 12, 2026
25d ago
8-K
NEUTRAL ★ 6/10
$6.53 $6.53· 0.00%▲ +0.00%$8.23 (+26.03%)
Apr 23, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$4.46 $4.88▲ +9.42%▲ +9.25%$8.23 (+84.53%)
Mar 19, 2026
11w ago
Press Release
MIXED ★ 6/10
$4.76 $5.48▲ +15.13%▲ +14.02%$8.23 (+72.90%)
Mar 17, 2026
11w ago
Press Release
MIXED ★ 5/10
$4.95 $5.20▲ +5.05%▲ +5.32%$8.23 (+66.26%)
Mar 12, 2026
12w ago
Press Release
BULLISH ★ 7/10
$5.03 $5.37▲ +6.76%▲ +7.36%$8.23 (+63.62%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (14h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access